ClinicalTrials.gg
CompletedNCT05101343Updated Jul 8, 2024Results posted

Use of Fitbits During Breathing Meditation

An interventional study of Breathing meditation in Healthy, sponsored by Winthrop University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-08.

Sponsored by Winthrop University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2021, registered Sep 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will examine short breathing meditations paired with Fitbit technology in order to assess mindfulness and track physical activity. Measures including heart rate, physical activity, sleep patterns, as well as assessments of well-being and anxiety levels, will be examined.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Winthrop University is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Older than 18 years.
  • Currently a student, faculty, or staff member at university where research is being completed.
  • Able to wear a Fitbit close to 24 hours a day for two weeks.

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years.
  • Has previously practiced meditation.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • No intervention
    Control

    Uses Fitbit, does not participate in breathing meditation.

  • Experimental
    Meditation

    Uses Fitbit and participates in brief, daily breathing meditation.

    Behavioral: Breathing meditation

Interventions

  • BehavioralBreathing meditation

    Daily, 5-minute breathing meditation for one week.

06

What researchers measure

Primary outcomes

  1. Change in Mindfulness

    Mindful Attention Awareness Scale (MAAS.) The trait MAAS is a 15-item scale designed to assess a core characteristic of mindfulness,namely, a receptive state of mind in which attention, informed by a sensitive awareness of what is occurring in the present, simply observes what is taking place. The survey consists of 15 questions using a Likert scale. Responses range from 1 (Almost Always) to 6 (Almost Never.)The scale is scored by computing a mean of the 15 items on the questionnaire. Score ranges of 15 (low) to 90 (high.) A higher score indicates a higher level of dispositional mindfulness.

    Time frame: Baseline and 2 weeks post-baseline

  2. Change in Anxiety

    Hospital Anxiety and Depression Scale (HADS). This questionnaire is used to measure anxiety and depression. Scale ranges are from 0 to 3. Lower values represent a better outcome. Total scores for depression and anxiety are summed. A score of 0-7 = normal. A score of 8-10 = borderline abnormal (borderline case.) A score of 11-21 = abnormal (case.)

    Time frame: Baseline and 2 weeks post-baseline

  3. Change in Well-being

    Mental Health Continuum Short Form (MHC-SF.) This questionnaire measures emotional, psychological, and social well-being. It consists of 14 questions scored on a Likert scale ranging from 0-5. Items 1-3 indicate emotional well-being (range 0-15). Items 4-8 indicate social well-being (0-25). Items 9-14 indicate psychological well-being (0-30). Total well-being score as reported here was calculated by adding the three sub-scores together (range 0-70). Higher scores indicate higher well-being for subscales and total well-being.

    Time frame: Baseline and 2 weeks post-baseline

  4. Change in Worry

    UMC (University Medical Centre) Penn State Worry Questionnaire. This is a 16 item questionnaire. Scale ranges from 0 (Not Typical at All) to 4 (Very Typical.) A higher score indicates a higher propensity for worry.

    Time frame: Baseline and 2 weeks post-baseline

  5. Change in Depression

    Hospital Anxiety and Depression Scale (HADS). This questionnaire is used to measure anxiety and depression. Scale ranges are from 0 to 3. Lower values represent a better outcome. Total scores for depression and anxiety are summed. A score of 0-7 = normal. A score of 8-10 = borderline abnormal (borderline case.) A score of 11-21 = abnormal (case.)

    Time frame: Baseline and 2 weeks post-baseline

Secondary outcomes

  1. Change in Sleep Minutes

    Duration of sleep in minutes as measured using Fitbit. An increase in duration of sleep indicated improvement.

    Time frame: Baseline and 2 weeks

  2. Change in Heart Rate

    Changes in heart rate in beats per minute as measured by Fitbit (average observed heart rate during Week 2 minus the average heart rate observed during Week 1)

    Time frame: Baseline and 2 weeks

  3. Change in Steps

    Change in number of steps taken as measured by Fitbit (average number of steps taken during Week 2 minus the average number of steps taken during Week 1)

    Time frame: Baseline and 2 weeks

  4. Change in Physically Active Minutes

    Amount of time spent being physically active in minutes as reported by Fitbit. An increase in time spent being physically active indicated improvement.

    Time frame: Baseline and 2 weeks

07

Results

Posted Jul 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneControlMeditation
Started1918
Completed1717
Not completed21
Withdrew: Withdrawal by subject21

Outcome measures

PrimaryChange in Mindfulness

Mindful Attention Awareness Scale (MAAS.) The trait MAAS is a 15-item scale designed to assess a core characteristic of mindfulness,namely, a receptive state of mind in which attention, informed by a sensitive awareness of what is occurring in the present, simply observes what is taking place. The survey consists of 15 questions using a Likert scale. Responses range from 1 (Almost Always) to 6 (Almost Never.)The scale is scored by computing a mean of the 15 items on the questionnaire. Score ranges of 15 (low) to 90 (high.) A higher score indicates a higher level of dispositional mindfulness.

Time frame:
Baseline and 2 weeks post-baseline
Reported as:
Mean · score on a scale
Change in Mindfulness
score on a scaleControlMeditation
Change in Mindfulness-0.08 ± 0.570.1 ± 0.43
PrimaryChange in Anxiety

Hospital Anxiety and Depression Scale (HADS). This questionnaire is used to measure anxiety and depression. Scale ranges are from 0 to 3. Lower values represent a better outcome. Total scores for depression and anxiety are summed. A score of 0-7 = normal. A score of 8-10 = borderline abnormal (borderline case.) A score of 11-21 = abnormal (case.)

Time frame:
Baseline and 2 weeks post-baseline
Reported as:
Mean · score on a scale
Change in Anxiety
score on a scaleControlMeditation
Change in Anxiety-.18 ± 2.27-2.35 ± 3.64
PrimaryChange in Well-being

Mental Health Continuum Short Form (MHC-SF.) This questionnaire measures emotional, psychological, and social well-being. It consists of 14 questions scored on a Likert scale ranging from 0-5. Items 1-3 indicate emotional well-being (range 0-15). Items 4-8 indicate social well-being (0-25). Items 9-14 indicate psychological well-being (0-30). Total well-being score as reported here was calculated by adding the three sub-scores together (range 0-70). Higher scores indicate higher well-being for subscales and total well-being.

Time frame:
Baseline and 2 weeks post-baseline
Reported as:
Mean · score on a scale
Change in Well-being
score on a scaleControlMeditation
Change in Well-being3.00 ± 8.893.75 ± 10.33
PrimaryChange in Worry

UMC (University Medical Centre) Penn State Worry Questionnaire. This is a 16 item questionnaire. Scale ranges from 0 (Not Typical at All) to 4 (Very Typical.) A higher score indicates a higher propensity for worry.

Time frame:
Baseline and 2 weeks post-baseline
Reported as:
Mean · score on a scale
Change in Worry
score on a scaleControlMeditation
Change in Worry-0.13 ± 7.03-1.59 ± 6.05
PrimaryChange in Depression

Hospital Anxiety and Depression Scale (HADS). This questionnaire is used to measure anxiety and depression. Scale ranges are from 0 to 3. Lower values represent a better outcome. Total scores for depression and anxiety are summed. A score of 0-7 = normal. A score of 8-10 = borderline abnormal (borderline case.) A score of 11-21 = abnormal (case.)

Time frame:
Baseline and 2 weeks post-baseline
Reported as:
Mean · units on a scale
Change in Depression
units on a scaleControlMeditation
Change in Depression-1.12 ± 2.57-0.53 ± 2.90
SecondaryChange in Sleep Minutes

Duration of sleep in minutes as measured using Fitbit. An increase in duration of sleep indicated improvement.

Time frame:
Baseline and 2 weeks
Reported as:
Mean · Duration of sleep in minutes
Change in Sleep Minutes
Duration of sleep in minutesControlMeditation
Change in Sleep Minutes-10.76 ± 36.476.33 ± 21.43
SecondaryChange in Heart Rate

Changes in heart rate in beats per minute as measured by Fitbit (average observed heart rate during Week 2 minus the average heart rate observed during Week 1)

Time frame:
Baseline and 2 weeks
Reported as:
Mean · Beats per minute of heart
Change in Heart Rate
Beats per minute of heartControlMeditation
Change in Heart Rate-0.49 ± 1.75-0.12 ± 2.84
SecondaryChange in Steps

Change in number of steps taken as measured by Fitbit (average number of steps taken during Week 2 minus the average number of steps taken during Week 1)

Time frame:
Baseline and 2 weeks
Reported as:
Mean · number of steps taken
Change in Steps
number of steps takenControlMeditation
Change in Steps-56.12 ± 1186.91271.96 ± 1678.45
SecondaryChange in Physically Active Minutes

Amount of time spent being physically active in minutes as reported by Fitbit. An increase in time spent being physically active indicated improvement.

Time frame:
Baseline and 2 weeks
Reported as:
Mean · Duration of physical activity minutes
Change in Physically Active Minutes
Duration of physical activity minutesControlMeditation
Change in Physically Active Minutes-7.45 ± 33.453.02 ± 49.7

Adverse events

Collected over Through study completion, an average of 2 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control0/17 (0%)0/17 (0%)0/17 (0%)
Meditation0/17 (0%)0/17 (0%)0/17 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ControlMeditationTotal
<=18 years000
Between 18 and 65 years171734
>=65 years000
Age, Continuous
Age, Continuous(years)ControlMeditationTotal
Mean34 ± 1431 ± 1334 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)ControlMeditationTotal
Female141226
Male358
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ControlMeditationTotal
White10818
Black or African American167
Hispanic/Latino/Spanish202
Asian202
Multi-racial224
Prefer not to answer011
Region of Enrollment
Region of Enrollment(participants)ControlMeditationTotal
United States171734
08

Study locations

1 site
  • Winthrop University
    Rock Hill, South Carolina 29733, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Oct 2021, 7 months.

Results were first posted in Jul 2024, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2021
First posted
Nov 1, 2021
StartActual
Mar 1, 2021
Primary completionActual
Oct 6, 2021
CompletionActual
Oct 6, 2021
Results first posted
Jul 8, 2024
Last update
Jul 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05101343
Lead sponsor
Winthrop University
Responsible party
Sponsor
First posted
Nov 1, 2021
Start date
Mar 1, 2021
Primary completion
Oct 6, 2021
Completion
Oct 6, 2021
Results posted
Jul 8, 2024
Last update
Jul 8, 2024

Study contacts

Courtney Guenther
principal investigator · Winthrop University - Rock Hill, SC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion